FDA Grants Accelerated Approval to Tovorafenib

426 Views

Emedinexus 06 May 2025

The Food and Drug Administration granted accelerated approval to tovorafenib for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.